BioLineRx Ltd. (NASDAQ:BLRX – Get Free Report) was the recipient of a large decrease in short interest in May. As of May 15th, there was short interest totalling 219,100 shares, a decrease of 46.6% from the April 30th total of 410,600 shares. Based on an average daily volume of 410,600 shares, the short-interest ratio is […]
StockNews.com upgraded shares of BioLineRx (NASDAQ:BLRX – Free Report) to a sell rating in a report published on Tuesday morning. Separately, HC Wainwright reissued a buy rating and issued a $21.00 price objective on shares of BioLineRx in a research note on Wednesday, April 17th. View Our Latest Analysis on BioLineRx BioLineRx Stock Performance NASDAQ:BLRX […]
BioLineRx (NASDAQ:BLRX – Get Free Report) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Tuesday. Separately, HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of BioLineRx in a report on Wednesday, April 17th. Check Out Our […]
BioLineRx (NASDAQ:BLRX – Get Free Report) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a research report issued on Tuesday. Separately, HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of BioLineRx in a research note on Wednesday, April 17th. Check Out Our Latest Report […]
HC Wainwright reaffirmed their buy rating on shares of BioLineRx (NASDAQ:BLRX – Free Report) in a research report report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $21.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for BioLineRx’s Q1 2024 earnings at ($0.29) EPS, Q2 2024 earnings at […]